We have developed a new ELISA for quantifying N-acetyl-␤-D-glucosaminidase (NAG) isoenzyme B in human urine after raising monoclonal antibodies against the isoenzyme from human placenta. Though the obtained antibodies reacted not only to isoenzyme B but also to A, we could detect isoenzyme B selectively by a two-step sandwich ELISA with a pair of selected antibodies at low pH in the first reaction. The detected limit was 0.5 g/L for a sample volume of 25 L. Within-run CVs ranged from 2.5% to 5.4% and betweenrun CVs ranged from 6.2% to 9.1%. Recoveries of NAG isoenzyme B added to each of three urine samples ranged from 91% to 114%. The dilution curves of urine samples showed good linearity. The cross-reactivity of NAG isoenzyme A was practically negligible (2-3%). The mean value for NAG isoenzyme B in spot urines from healthy adults was 2.9 g/g creatinine. This ELISA method is rapid and precise enough for routine determination of NAG isoenzyme B in human urine. INDEXING TERMS: monoclonal antibody • renal damage • immunological activity
N-Acetyl-␤-d-glucosaminidase (NAG; EC 3.2.1.30) is a widely distributed lysosomal enzyme located predominantly in the renal proximal tubules [1] . 3 Increased NAG enzymatic activity in urine has been found to be associated with various kidney injuries [2, 3] . It is considered to be a sensitive marker of renal diseases, an early warning of rejection after renal transplantation [4] , and a sign of drug nephrotoxicity [5] . NAG enzymatic activity in urines has been determined fluorometrically with 4-methylumbelliferyl-N-acetyl-␤-d-glucosaminide [6] , and colorimetrically with p-nitrophenyl-N-acetyl-␤-d-glucosaminide [7] or sodio m-cresolsulfophthaleinyl-N-acetyl-␤-d-glucosaminide [8] .
NAG can be separated into two major isoenzymes, A and B, and several other minor isoenzymes (I, P, S) [9] . NAG isoenzyme A is composed of two different subunits ␣ and ␤, whereas NAG isoenzyme B, and probably I, consist of two ␤-subunits [10 -12] . These isoenzymes differ in pI, substrate specificity, and thermal stability. There have been many reports describing the possible clinical significance of NAG isoenzyme analysis and especially of using NAG isoenzymes B and I, which are present at 10 -20% in normal human urine, as more sensitive markers of various types of renal damage than total NAG [13] [14] [15] [16] [17] [18] .
The separation of NAG isoenzyme B from A has been performed by ion-exchange chromatography, electrophoresis, and a method that takes advantage of the thermoinstability of NAG isoenzyme A. However, these methods are time consuming, not precise, and (or) not easily adapted to routine clinical work. Therefore, rapid and highly sensitive methods for more extensive evaluation are needed for NAG isoenzyme B [and (or) I] determination. Here, we describe a new ELISA method for NAG isoenzyme B (and I) that is based on a two-step sandwich assay involving two anti-NAG monoclonal antibodies and microplates as the solid phase.
Materials and Methods antibodies
Monoclonal antibodies against NAG isoenzyme B were raised by using partially purified NAG isoenzyme B from human placentas (Sigma Chemical Co., St. Louis, MO). Hybridomas were produced in accordance with conven-tional procedure [19] . In the screening method, wells of microplates (module plate F8; Nunc, Roskilde, Denmark) were coated with goat anti-mouse immunoglobulins. Hybridoma supernatants were added to the wells and the wells were incubated at room temperature for 2 h. The wells were washed with PBS (10 mmol/L, pH 7.4) containing 0.5 mL/L Tween 20. Partially purified NAG isoenzyme was then added, followed by further incubation. After washing, the specific antibodies were detected by assaying NAG enzymatic activity in the wells.
Isotype determination was carried out by the enzyme immunoassay method with an isotyping kit (PharMingen, San Diego, CA).
purified nag isoenzymes a and b
NAG isoenzymes A and B were purified from human placentas by procedures including chromatographies on concanavalin A-Sepharose (Pharmacia, Uppsala, Sweden), an immunoadsorbent column, Mono Q Sepharose (Pharmacia), and Superose 12 column (Pharmacia) by the method of Kinoshita et al. [12] . For preparation of the immunoadsorbent column, anti-NAG monoclonal antibody, Hex 33, was immobilized to a protein G-Sepharose 4 Fast Flow column (Pharmacia) according to Schneider et al. [20] . The purities were checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein concentrations were determined by the method of Lowry et al. [21] . fabЈ-peroxidase conjugate A monoclonal antibody (Hex 32, IgG1, , 18 mg) was conjugated with horseradish peroxidase (HRP; EC 1.11.1.7) as described by Kato et al. [22] . When binding activities of NAG isoenzyme at various pHs were examined, the assay buffers used were citrate, 0.4 mol/L containing BSA (1 g/L), pH range 4.8 -5.6; and phosphate, 0.01 mol/L containing NaCl (9 g/L) and BSA (1 g/L), pH range 6.8 -8.0.
microplates coated with anti-nag monoclonal antibody
Each well of a microplate was filled with a solution (200 L) of anti-NAG antibody Hex 31 (10 mg/L in PBS) and incubated overnight at 4°C. After removal of the antibody solution, the wells were washed three times by filling them with washing solution and aspirating it out. PBS (300 L) containing saccharose (100 g/L) was added to each well of the microplates, which were then incubated at room temperature for 1 h. After aspiration, the microplates were dried in a desiccator under vacuum overnight and stored at 4°C.
elisa for determination of nag isoenzyme b
In the typical assay procedure, all incubations were performed at 30°C. Each well of the antibody-coated microplates was washed once with washing solution and assay buffer I (150 L) and aliquots of purified NAG isoenzyme B or urine (25 L each) were added to the wells. Incubation was for 2 h (first reaction). After this the wells were washed four times with washing solution, and Hex 32 FabЈ-HRP conjugate (25 ng) in assay buffer II (100 L) was added. The samples were left standing for 1 h (second reaction). The wells were again aspirated and washed four times, then substrate solution (100 L) added to each well. After 15 min of incubation (enzyme reaction), stop solution (100 L) was added and the absorbance at 415 nm was measured with immunoreader MTP-32 (Corona Electric Co., Ibaraki, Japan). Experiments were performed in duplicate except where noted otherwise. nag isoenzyme analysis NAG isoenzyme separation was carried out by ion-exchange chromatography with a fast protein liquid chromatography (FPLC) system (Pharmacia). The concentrated urine samples were dialyzed against 10 mmol/L phosphate buffer, pH 6.0 (buffer A), at 4°C overnight. A Mono Q column (0.5 ϫ 5.0 cm) was equilibrated with buffer A and 2 mL of dialyzed sample was applied to the column. NAG isoenzymes were eluted with 5 mL of buffer A and then with a linear NaCl gradient in buffer A at a flow rate of 1 mL/min. Fractions (1-mL) were collected and NAG activities were determined by both the enzyme assay and the ELISA.
nag enzyme assay
Enzymatic activity of NAG (total NAG) was measured by the sodio m-cresosulfophthaleinyl-N-acetyl-␤-d-glucosaminide method [8] with a commercially available kit (Shionogi, Osaka, Japan).
calculation of urinary nag isoenzyme b enzymatic activities
Urinary NAG isoenzyme B enzymatic activities were calculated by using the following equations: 
Results

characterization of anti-nag monoclonal antibodies
Cell fusions repeated twice gave six hybridoma clones that produced antibodies (Hex 31-36) reacting to the antigen (NAG isoenzyme B). Though a partially purified antigen was used as an immunogen, we could obtain anti-NAG monoclonal antibodies by assaying captured NAG enzymatic activities. All clones were IgG1 type with a light chain and reacted not only to NAG isoenzyme B but also to A. Among the preliminary sandwich assays involving combinations of the obtained antibodies, the assay involving Hex 31 and Hex 32 as an immobilized antibody and a labeled one, respectively, showed a dosedependent response to NAG isoenzyme B with great sensitivity. Therefore, we tried to develop an ELISA for NAG isoenzyme B with the pair of Hex 31 and Hex 32.
purities of nag isoenzymes a and b prepared from human placentas
Purified antigen as a calibrator was necessary for the ELISA. We purified NAG from human placentas by using an immunoadsorbent column. Finally, the NAG isoenzymes were purified 5900-fold for isoenzyme A and 6500-fold for isoenzyme B, respectively. The specific activities of isoenzymes A and B in our system were 142 and 164 U/mg protein. SDS-PAGE of NAG isoenzyme A showed two bands with molecular masses of 52 kDa and 60 kDa, which corresponded to the ␣ and ␤ chains (Fig. 1,  lane 1) . Only the ␤ chain was seen for NAG isoenzyme B (lane 2). After reduction of NAG isoenzymes A and B, the ␤ chain dissociated into two bands, ␤ a and ␤ b chains with molecular masses of 30 kDa and 28 kDa, respectively (lanes 3, 4). We used purified NAG isoenzyme B as the calibrator material of our ELISA.
optimization of assay phs
We tested the ELISA for cross-reactivity of NAG isoenzyme A at different pH values. When the pH of the second reaction was fixed at pH 7.4, the cross-reactivity of NAG isoenzyme A in the first reaction amounted to 14.0%, 6.4%, and 2.4% at pH 7.0, 6.0, and 5.2, respectively ( Fig. 2A) . Lower reactivity to NAG isoenzyme B was observed at pH 4.8. When the first reaction was carried out at a fixed pH of 5.2 and the cross-reactivity with NAG isoenzyme A was examined from pH 5.2 to 8.0 in the second reaction ( Fig. 2B) , there was little change in the crossreactivity. We therefore selected pH 5.2 for the first reaction to decrease the cross-reactivity with NAG isoenzyme A and pH 7.4 for the second reaction to increase the sensitivity.
assay characteristics
As shown in Fig. 3 , the absorbance at 415 nm against the amount of calibrator exhibited a linear relation in the range of 0 to 80 g/L. The lower detection limit of this ELISA, defined as the concentration at the mean ϩ 3SD of 20 determinations of the zero calibrator, was 0.5 g/L. The cross-reactivity with human NAG isoenzyme A was ϳ2-3% in the present ELISA, and no cross-reactivity with NAG from bovine kidney was observed (data not shown). The precision of the present ELISA was estimated with three different urine samples containing NAG isoenzyme B. The CVs for within-and between-assay series were 2.5-5.4% (n ϭ 8) and 6.2-9.1% (n ϭ 14), respectively, as shown in Table 1 . Recoveries of exogenously added NAG isoenzyme B from urine samples containing three different concentrations of endogenous NAG isoenzyme B were estimated ( Table 2 ). The recoveries ranged from 91% to 114%. Dilution curves of three urine samples showed good linearity, as shown in Fig. 4 . Possible interfering substances were investigated by the usual addition technique. Uric acid (1 g/L), ascorbic acid (10 g/L), glucose (100 g/L), albumin (10 g/L), creatinine (10 g/L), and hemoglobin (50 g/L) had no effect on the present ELISA. The components of our assay were stable for at least a year at 4°C.
ion-exchange chromatography of human urinary nag isoenzymes
To examine the isoenzyme selectivity of the present ELISA, the elution patterns of urinary NAG isoenzymes analyzed by ELISA were compared with those analyzed by the NAG enzyme assay. Fig. 5 shows ion-exchange chromatograms of a urine sample from a patient with renal damage. The ELISA responded to NAG isoenzymes B and I, but not to isoenzyme A. This result indicates that the amount of NAG isoenzyme B (and I) can be determined selectively in urinary samples. The linear regression between the values measured with the chromatographic method (x) and those determined by ELISA (y) yielded y ϭ 1.12x ϩ 0.59 U/L for 20 urine samples. ELISA was carried out as described in the text except for variation in pH. Solutions of NAG isoenzyme A (40 g/L) and isoenzyme B (40 g/L) were used. Arrows indicate the pHs used under the calibration conditions. Fig. 3 . Calibration curve for the ELISA of NAG isoenzyme B.
concentrations of nag isoenzyme b in human urine samples
NAG isoenzyme B excretion in the normal control group was 2.9 g/g creatinine (or 3.1 g/L) for spot collection (n ϭ 40, Table 3 ). The values showed no sex-related differences. The mean value of the percentage of isoenzyme B in total NAG was 15.8%, which agrees with earlier results obtained by the ion-exchange chromatography method [23] . Values of NAG isoenzyme B from pathological urine samples were also measured ( Table 3 ). Most of the urine from patients with renal diseases, especially pyelonephritis, showed significant increases in both values and percentages of NAG isoenzyme B.
Discussion
Ellis et al. [13] reported that in pathological urine, the excretion of NAG isoenzyme B was increased roughly in parallel with the increase in total NAG. Gibey et al. [16] demonstrated a significant increase in isoenzyme B activity after treatment with aminoglycoside antibiotics. Vigano et al. [15] showed a significant increase of NAG isoenzyme B in upper urinary tract infections. Others have also reported increase of urinary NAG isoenzyme B and (or) I during rejection of transplanted kidneys [17] or in glomerular diseases [23] . Although the analytical method for NAG isoenzyme separation, for example, electrophoresis or ion-exchange chromatography, can provide interesting information on the underlying diseases, they are too time consuming and uneconomical for clinical laboratories. Therefore, quantitative methods that satisfy the fundamental analytical criteria of within-and between-run precisions, sensitivity, specificity, and accuracy need to be developed for the determination of NAG isoenzymes, especially isoenzyme B. We raised monoclonal antibodies against human placental NAG to develop a new sandwich immunoassay for NAG isoenzyme B. All of the antibodies reacted with both NAG isoenzymes A and B, probably due to the presence of a common ␤-subunit. Isoenzyme B-specific antibodies could not be established, but we were able to develop a sandwich ELISA for selective determination of the NAG isoenzyme B by using a selected antibody pair at pH 5.2 in the first reaction. Although it was not clear why the cross-reactivity could be reduced at low pH, the decrease in immunoreactivity seems to be due to a conformational change of NAG isoenzyme A. In human urine, the amount of NAG detected by the present ELISA also reflected those of isoenzymes B and I (Fig. 5 ). NAG isoenzyme I, an acidic variant of NAG isoenzyme B, may result from sialylation or phosphorylation at the carbohydrate moiety [12] . Our ELISA method is rapid, sensitive, and precise without the need for concentration and dialysis of urinary samples. Previously, Isaksson et al. [24, 25] raised monoclonal antibodies against human placental NAG and developed enzyme immunoassays for NAG isoenzymes A and B. However, these immunoassays were not sandwich assays but antigen-capture assays, in which the analytical accuracy was unclear and the detection was based on both the enzymatic and immunological activities of NAG. In general, immunological activity is thought to be stable relative to enzymatic activity as described for prostatic acid phosphatase [26] . Consequently, our immunoassay is expected to have two advantages over the measurement of total NAG enzymatic activity: high selectivity for isoenzyme B and detection on the basis of the immunological activity alone.
